NCT03282838已完成1 期
Open-Label, Three Way, Randomized, Single Dose Crossover Study Comparing Bioavailability of DFN-15 Oral Solution Under Fasting Conditions vs Comparator Under Fed Conditions and to Determine Food Effect of DFN-15 in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- DFN-15 maximum plasma concentration (Cmax)
研究概览
简要总结
An Open-Label, Three-Way Randomized, Single Dose Crossover Study Comparing Bioavailability of DFN-15 under fasting conditions versus Comparator under fed conditions and to determine food-effect of DFN-15 in Healthy Adult Subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy, adult, male or female 19-55 years of age, inclusive, at screening.
- •Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee.
- •Females of childbearing potential: must either be sexually inactive (abstinent) for 30 days prior to the first dose and throughout the study or be using birth control method; Female subjects of non-childbearing potential and must have undergone sterilization procedures or be postmenopausal for at least 1 year prior
- •Male subject must agree to use contraception or abstain during the study until 90 days beyond the last dose of study drug.
- •Understands the study procedures in the informed consent form (ICF), and willing and able to comply with the protocol.
排除标准
- •History or presence of hypersensitivity or idiosyncratic reaction to celecoxib, sulfonamides, aspirin or other NSAIDs or related compounds
- •History or presence of clinically significant medical or psychiatric condition or disease
- •History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study
- •liver enzyme tests greater than the upper limit of normal at screening
- •Estimated creatinine clearance <90 mL/minute at screening
- •History or presence of alcoholism
- •History or presence of bilateral pedal edema or generalized edema or fluid retention
- •Female subjects who are pregnant or lactating or actively trying to conceive
- •Positive urine drug or alcohol results at screening or check-in
- •Positive cotinine at screening
- •Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)
- •Seated blood pressure is less than 90/60 mmHg or greater than 140/90 mmHg at screening
- •Seated heart rate is lower than 45 bpm or higher than 100 bpm at screening
- •Has been on a diet incompatible with the on-study diet
- •Unable to refrain from or anticipates the use of prohibited medications
- •Donation of blood or significant blood loss within 56 days prior to the first dose of study drug; plasma donation within 7 days prior to the first dose of study drug
- •Participation in another clinical trial within 28 days prior to the first dose of study drug
研究组 & 干预措施
DFN-15 (fasted)
Experimental
干预措施: DFN-15 (fasted) (Drug)
DFN-15 (fed)
Experimental
干预措施: DFN-15 (fed) (Drug)
Comparator (fed)
Experimental
干预措施: Comparator Celebrex® (fed) (Drug)
结局指标
主要结局
DFN-15 maximum plasma concentration (Cmax)
时间窗: Up to 72 hours
DFN-15 area under the curve (AUC) 0-t
时间窗: Up to 72 hours
DFN-15 area under the curve (AUC) 0-inf
时间窗: Up to 72 hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioavailability of DFN-15 at 3 Different Doses vs. Comparator and to Determine Dose-proportionality of DFN-15 in Fasting Healthy AdultsHealthyNCT03051685Dr. Reddy's Laboratories Limited16
已完成
不适用
Comparative Single-dose Bioavailability Study of Different CoQ10 FormulationsBioavailability of Coenzyme Q10NCT04780074Nutrition Institute, Slovenia30
已完成
1 期
Pharmacokinetic Comparisons of Two Donepezil FormulationsAlzheimer DiseaseNCT01297036Korea University Anam Hospital22
已完成
1 期
Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine and Losartan in Health VolunteersHypertensionNCT01648231GlaxoSmithKline23
已完成
1 期
AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy SubjectsHealthyNCT02163161Pfizer12